 Timothy Garrington
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 2 | 2024 | 177 | 0.660 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 65 | 0.550 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 103 | 0.540 |
Why?
| | MAP Kinase Kinase Kinases | 6 | 2004 | 70 | 0.500 |
Why?
| | Kidney Neoplasms | 4 | 2025 | 415 | 0.470 |
Why?
| | Mitogen-Activated Protein Kinases | 8 | 2004 | 288 | 0.390 |
Why?
| | Hodgkin Disease | 2 | 2016 | 172 | 0.360 |
Why?
| | Wilms Tumor | 2 | 2025 | 90 | 0.330 |
Why?
| | Neuroblastoma | 3 | 2017 | 174 | 0.310 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 4 | 2004 | 126 | 0.290 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2008 | 7 | 0.290 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2014 | 98 | 0.280 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 161 | 0.280 |
Why?
| | Neoplasms | 6 | 2025 | 2913 | 0.280 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 58 | 0.270 |
Why?
| | Asparaginase | 2 | 1998 | 32 | 0.270 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 5 | 2004 | 153 | 0.270 |
Why?
| | MAP Kinase Kinase Kinase 1 | 3 | 2005 | 19 | 0.260 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 70 | 0.260 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 343 | 0.260 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2020 | 36 | 0.260 |
Why?
| | Child | 25 | 2025 | 22740 | 0.250 |
Why?
| | Pancreatitis | 2 | 1998 | 146 | 0.250 |
Why?
| | MAP Kinase Kinase Kinase 2 | 7 | 2012 | 12 | 0.230 |
Why?
| | Teratoma | 2 | 2025 | 124 | 0.230 |
Why?
| | Child, Preschool | 18 | 2025 | 11868 | 0.230 |
Why?
| | Mast Cells | 3 | 2003 | 148 | 0.230 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 111 | 0.220 |
Why?
| | Nose Neoplasms | 1 | 2025 | 22 | 0.220 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2003 | 426 | 0.220 |
Why?
| | Carcinosarcoma | 1 | 2025 | 23 | 0.220 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 66 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.210 |
Why?
| | Appointments and Schedules | 1 | 2025 | 96 | 0.210 |
Why?
| | Paclitaxel | 1 | 2025 | 259 | 0.200 |
Why?
| | Adolescent | 20 | 2025 | 22577 | 0.200 |
Why?
| | Medical Errors | 1 | 2025 | 119 | 0.200 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 94 | 0.200 |
Why?
| | Hematology | 1 | 2023 | 21 | 0.190 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 123 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 76 | 0.190 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1329 | 0.190 |
Why?
| | Central Nervous System Diseases | 1 | 2024 | 74 | 0.190 |
Why?
| | MAP Kinase Signaling System | 3 | 2008 | 308 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 102 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2025 | 265 | 0.180 |
Why?
| | Pediatrics | 3 | 2023 | 1125 | 0.180 |
Why?
| | Parental Leave | 1 | 2022 | 27 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2668 | 0.180 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 165 | 0.180 |
Why?
| | Anemia | 1 | 2023 | 191 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 361 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2023 | 204 | 0.170 |
Why?
| | Medical Oncology | 2 | 2023 | 340 | 0.170 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.170 |
Why?
| | Sarcoma | 2 | 2015 | 207 | 0.170 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 83 | 0.170 |
Why?
| | Pituitary Diseases | 1 | 2020 | 20 | 0.160 |
Why?
| | Stem Cell Factor | 1 | 2000 | 16 | 0.160 |
Why?
| | Program Evaluation | 2 | 2023 | 944 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2770 | 0.160 |
Why?
| | Ribonuclease III | 1 | 2021 | 43 | 0.160 |
Why?
| | Cholestasis | 1 | 2023 | 214 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 46 | 0.160 |
Why?
| | Receptors, IgE | 1 | 2000 | 43 | 0.160 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.160 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2020 | 16 | 0.160 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 84 | 0.160 |
Why?
| | Pituitary Gland | 1 | 2020 | 149 | 0.160 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 29 | 0.150 |
Why?
| | Fibroblasts | 3 | 2005 | 1028 | 0.150 |
Why?
| | Infant | 12 | 2025 | 10091 | 0.150 |
Why?
| | Humans | 40 | 2025 | 145783 | 0.150 |
Why?
| | Survival Rate | 3 | 2019 | 2094 | 0.140 |
Why?
| | Salvage Therapy | 2 | 2025 | 165 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 354 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 224 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1150 | 0.140 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 71 | 0.140 |
Why?
| | Disease-Free Survival | 2 | 2019 | 770 | 0.140 |
Why?
| | Octreotide | 1 | 1998 | 23 | 0.130 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 15 | 0.130 |
Why?
| | Female | 23 | 2025 | 79045 | 0.130 |
Why?
| | Male | 23 | 2025 | 73010 | 0.130 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 47 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 340 | 0.130 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.120 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.120 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2020 | 784 | 0.120 |
Why?
| | Cytokines | 2 | 2004 | 2069 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2003 | 1217 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2022 | 338 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1969 | 0.120 |
Why?
| | Enzyme Activation | 6 | 2004 | 762 | 0.120 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 473 | 0.120 |
Why?
| | Quality Improvement | 1 | 2025 | 1296 | 0.120 |
Why?
| | Health Planning | 1 | 2015 | 47 | 0.110 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1999 | 414 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2025 | 17330 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2005 | 79 | 0.100 |
Why?
| | Thoracoscopy | 1 | 2014 | 60 | 0.100 |
Why?
| | Mediastinal Neoplasms | 1 | 2014 | 53 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 596 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2399 | 0.100 |
Why?
| | Biopsy | 1 | 2017 | 1082 | 0.100 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.100 |
Why?
| | Carrier Proteins | 4 | 2003 | 729 | 0.100 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 21 | 0.100 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2013 | 6 | 0.100 |
Why?
| | Histiocytosis, Sinus | 1 | 2013 | 7 | 0.100 |
Why?
| | Disease Management | 2 | 2015 | 653 | 0.100 |
Why?
| | Transition to Adult Care | 1 | 2015 | 103 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 106 | 0.090 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 269 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1505 | 0.090 |
Why?
| | Heart Diseases | 1 | 2016 | 341 | 0.090 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2012 | 149 | 0.090 |
Why?
| | Prognosis | 5 | 2025 | 4330 | 0.090 |
Why?
| | Prevalence | 1 | 2019 | 2875 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 337 | 0.090 |
Why?
| | Gene Expression Regulation | 4 | 2012 | 2601 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2002 | 162 | 0.080 |
Why?
| | Anesthesia | 1 | 2014 | 257 | 0.080 |
Why?
| | Signal Transduction | 3 | 2004 | 5224 | 0.080 |
Why?
| | Program Development | 2 | 2015 | 368 | 0.080 |
Why?
| | Ventricular Remodeling | 1 | 2012 | 278 | 0.080 |
Why?
| | Stem Cells | 2 | 2008 | 630 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2009 | 26 | 0.080 |
Why?
| | Laparoscopy | 1 | 2014 | 481 | 0.080 |
Why?
| | Primary Health Care | 2 | 2022 | 1737 | 0.070 |
Why?
| | Young Adult | 7 | 2025 | 14254 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 205 | 0.070 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2008 | 55 | 0.070 |
Why?
| | Mutation | 4 | 2025 | 4090 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2012 | 546 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1043 | 0.070 |
Why?
| | Heart Ventricles | 1 | 2012 | 756 | 0.070 |
Why?
| | Adult | 7 | 2025 | 40881 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 2219 | 0.060 |
Why?
| | Embryo, Mammalian | 2 | 2005 | 234 | 0.060 |
Why?
| | Infant, Newborn | 4 | 2023 | 6465 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 4 | 2012 | 16 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 246 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2012 | 777 | 0.060 |
Why?
| | Near Miss, Healthcare | 1 | 2025 | 12 | 0.060 |
Why?
| | Epidermal Growth Factor | 2 | 2003 | 162 | 0.060 |
Why?
| | Cell Line | 5 | 2003 | 2823 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3752 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3346 | 0.060 |
Why?
| | Acute Disease | 2 | 1998 | 1036 | 0.050 |
Why?
| | Hypoxia | 1 | 2012 | 1199 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2005 | 54 | 0.050 |
Why?
| | Transcription Factors | 2 | 2021 | 1736 | 0.050 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 208 | 0.050 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 103 | 0.050 |
Why?
| | SEER Program | 2 | 2016 | 230 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 481 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 81 | 0.050 |
Why?
| | Phosphorylation | 3 | 2012 | 1708 | 0.050 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 24 | 0.050 |
Why?
| | Apoptosis | 3 | 2002 | 2444 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2025 | 188 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2025 | 178 | 0.050 |
Why?
| | Blotting, Western | 2 | 2004 | 1184 | 0.050 |
Why?
| | Genes, jun | 1 | 2003 | 9 | 0.050 |
Why?
| | Myogenic Regulatory Factors | 1 | 2003 | 45 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 688 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1378 | 0.050 |
Why?
| | DNA Methylation | 1 | 2008 | 690 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 365 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 254 | 0.050 |
Why?
| | Macromolecular Substances | 2 | 2003 | 216 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2005 | 1247 | 0.050 |
Why?
| | src-Family Kinases | 1 | 2003 | 92 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 297 | 0.050 |
Why?
| | Tissue Donors | 1 | 2005 | 420 | 0.050 |
Why?
| | Animals | 9 | 2012 | 38101 | 0.040 |
Why?
| | Mice | 6 | 2012 | 18355 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2012 | 3130 | 0.040 |
Why?
| | Recurrence | 3 | 2013 | 1139 | 0.040 |
Why?
| | Survivors | 2 | 2016 | 523 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2000 | 2050 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2025 | 554 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2005 | 4151 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 431 | 0.040 |
Why?
| | Central Nervous System | 1 | 2024 | 282 | 0.040 |
Why?
| | Databases, Factual | 2 | 2018 | 1491 | 0.040 |
Why?
| | Survivorship | 1 | 2022 | 57 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 30 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 31 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1957 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 24 | 0.040 |
Why?
| | Receptor Aggregation | 1 | 2000 | 10 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2005 | 1454 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 735 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 120 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 52 | 0.040 |
Why?
| | Reoviridae | 1 | 2000 | 38 | 0.040 |
Why?
| | Curriculum | 1 | 2007 | 1074 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 38 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 381 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 177 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 376 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 264 | 0.040 |
Why?
| | Mating Factor | 1 | 1999 | 2 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6085 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1999 | 53 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1999 | 52 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 625 | 0.040 |
Why?
| | Growth Substances | 1 | 1999 | 138 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1450 | 0.040 |
Why?
| | Insect Proteins | 1 | 1999 | 40 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 74 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5428 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2000 | 372 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1999 | 143 | 0.030 |
Why?
| | Age of Onset | 1 | 2020 | 557 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1777 | 0.030 |
Why?
| | MAP Kinase Kinase 5 | 3 | 2003 | 4 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1812 | 0.030 |
Why?
| | Cytoskeleton | 1 | 1999 | 192 | 0.030 |
Why?
| | Dexamethasone | 1 | 2020 | 365 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 499 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 562 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 971 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1482 | 0.030 |
Why?
| | Mammals | 1 | 1999 | 286 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1271 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1043 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 372 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Drosophila melanogaster | 1 | 1999 | 239 | 0.030 |
Why?
| | Hepatoblastoma | 1 | 2017 | 52 | 0.030 |
Why?
| | Microtubules | 1 | 1999 | 265 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2934 | 0.030 |
Why?
| | United States | 3 | 2022 | 16126 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 478 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 443 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 70 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 1999 | 327 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 119 | 0.030 |
Why?
| | Neurilemmoma | 1 | 2014 | 25 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1999 | 574 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7134 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 201 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 699 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1407 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 999 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3418 | 0.020 |
Why?
| | MAP Kinase Kinase 7 | 2 | 2003 | 8 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1475 | 0.020 |
Why?
| | Lymphoma | 1 | 2014 | 241 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2139 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2000 | 2805 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1300 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2000 | 1998 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 2 | 2003 | 59 | 0.020 |
Why?
| | Colorado | 2 | 2015 | 4556 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2002 | 31 | 0.020 |
Why?
| | fas Receptor | 2 | 2002 | 91 | 0.020 |
Why?
| | Caspases | 2 | 2002 | 233 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 507 | 0.020 |
Why?
| | Transfection | 2 | 2003 | 927 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2020 | 11794 | 0.020 |
Why?
| | Aged | 2 | 2022 | 26217 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 64 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 788 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 112 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 175 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1372 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 298 | 0.020 |
Why?
| | Schools, Medical | 1 | 2007 | 159 | 0.010 |
Why?
| | Clinical Clerkship | 1 | 2007 | 109 | 0.010 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 928 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 552 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2005 | 123 | 0.010 |
Why?
| | Protein Binding | 2 | 2003 | 2240 | 0.010 |
Why?
| | Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 48 | 0.010 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2005 | 25 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2005 | 149 | 0.010 |
Why?
| | Prospective Studies | 1 | 2017 | 8078 | 0.010 |
Why?
| | Dimerization | 1 | 2005 | 189 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 419 | 0.010 |
Why?
| | Faculty, Medical | 1 | 2007 | 305 | 0.010 |
Why?
| | Middle Aged | 2 | 2017 | 36309 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1165 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8347 | 0.010 |
Why?
| | MEF2 Transcription Factors | 1 | 2003 | 51 | 0.010 |
Why?
| | Mink | 1 | 2003 | 11 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1062 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 279 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 168 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 219 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1547 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4568 | 0.010 |
Why?
| | Caspase 3 | 1 | 2002 | 242 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2005 | 588 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2171 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1764 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2000 | 4 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2000 | 9 | 0.010 |
Why?
| | Caspase 8 | 1 | 2000 | 48 | 0.010 |
Why?
| | Caspase 9 | 1 | 2000 | 55 | 0.010 |
Why?
| | COS Cells | 1 | 2000 | 177 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2883 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 54 | 0.010 |
Why?
| | Oxidants | 1 | 2000 | 99 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 383 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2000 | 159 | 0.010 |
Why?
| | Caspase Inhibitors | 1 | 2000 | 81 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 440 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 187 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 335 | 0.010 |
Why?
| | Mitosis | 1 | 1999 | 193 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1133 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2003 | 1134 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2003 | 1360 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1497 | 0.010 |
Why?
|
|
Garrington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|